What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
News|Articles|April 1, 2025
Allergy Month in Review: March 2025
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
March Allergy Updates: FDA approved the first biosimilar for omalizumab, epicutaneous and oral immunotherapy trials showed promise, and experts discussed allergy trends.
Advertisement
Advertisement
March brought a mix of challenges and advancements in healthcare. Anaphylaxis treatment remains underwhelming, with many not receiving the guideline-recommended adrenaline. Climate change further exacerbated allergy season, lengthening pollen exposure and triggering new conditions such as alpha-gal syndrome.
Related to this article
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.
Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.
A multi-site qualitative study identifies communication, language, and access barriers standing in the way of removing incorrect penicillin allergy labels.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.
Advertisement
Advertisement